with paroxetine; the actual dose of metoprolol can be determined by titration on the basis of its clinically measured cardiovascular effects. It may also be safer for patients to receive metoprolol ER than metoprolol IR when paroxetine and metoprolol are prescribed together.
Mechanism of the Interaction Between Paroxetine and Metoprolol
Paroxetine is a potent inhibitor of CYP2D6, 10, 11 the enzyme that plays a major role in the metabolism of metoprolol. 3 This explains why paroxetine increases pharmacokinetic indices of exposure to metoprolol and, hence, the cardiovascular effects of metoprolol.
Other Antidepressants and Other β-Blockers
The interaction between antidepressants and β-blockers can be anticipated if one knows how individual β-blockers are metabolized or eliminated (Table 2 ) and the effects of individual antidepressants on the CYP enzyme system (Table 3) . It is apparent that most of the commonly used β-blockers are either metabolized by CYP2D6 or eliminated by renal excretion 3, [12] [13] [14] [15] [16] [17] [18] [19] ; thus, an awareness of which commonly used antidepressants significantly inhibit CYP2D6 10, 11, [20] [21] [22] [23] [24] [25] will warn clinicians about the risk of a potential drug interaction. Table 3 also lists antidepressants that are mild inhibitors of CYP2D6 10, 23, 25, 26, [29] [30] [31] ; these are probably associated with lower risk of CYP2D6 drug interactions at usual clinical doses.
There is evidence to show that the data in Tables 2 and 3 can reasonably be extrapolated to real-life practice. For example, in a pharmacokinetic study 23 in healthy human volunteers, duloxetine, escitalopram, and sertraline all increased exposure to metoprolol: whereas sertraline increased the metoprolol AUC by over 50%, escitalopram nearly doubled the AUC, and duloxetine nearly trebled it. Furthermore, whereas sertraline increased the maximum concentration (C max ) of metoprolol by 38%, the C max was doubled by both escitalopram and duloxetine. Increases in C max and AUC both predict an increased likelihood of physiologic and adverse effects of a drug.
In other reports and studies, paroxetine doubled the AUC of carvedilol in healthy volunteers, 32 and fluoxetine increased the exposure to metoprolol 33 and nebivolol.
14 Propranolol is mainly metabolized by CYP1A2 and 2D6, but other CYP enzymes (including CYP2C19 and 3A4) also participate in its breakdown. 15, 16 An important implication here is that if only 1 enzyme is inhibited (eg, CYP2D6, by paroxetine), the activity of the remaining enzymes will help ensure that propranolol pharmacokinetics are not excessively impacted. However, fluvoxamine, which potently inhibits CYP1A2 30 and 2C19 34 and less potently inhibits CYP2D6 and 3A4, 29, 30 can be expected to increase levels of propranolol 35 and hence its biological effects.
Are the Interactions Clinically Significant?
Single-dose pharmacokinetic studies in healthy volunteers may not identify significant cardiovascular changes associated with the drug interactions described. For Some antidepressants inhibit the metabolism of some β-blockers.
■
Bradycardia and hypotension, heart block, or other dose-dependent adverse ■ effects may occur in vulnerable patients as a result of these interactions.
Strategies include prescribing an antidepressant that does not affect the ■ metabolism of the β-blocker in use, or prescribing a β-blocker that is not metabolized by the antidepressant in use.
If the interaction is unavoidable, the β-blocker dose can be down-titrated using ■ heart rate and blood pressure as a guide. The effect of paroxetine on the C max of S-metoprolol was significantly greater for the IR formulation of metoprolol than for either of the (100-and 200-mg) ER formulations
Paroxetine significantly enhanced the metoprolol-induced fall in exercise-related heart rate and systolic blood pressure
The peak effect of the 2 doses (spaced 12 h apart) of metoprolol IR 100 mg on heart rate was significantly greater than that of the single dose of metoprolol ER 200 mg. This finding was not altered by paroxetine administration a Data from Parker and Soberman. example, Stout et al 32 found that although paroxetine doubled the AUC of carvedilol in healthy volunteers, there were no clinically significant changes in heart rate, blood pressure, or PR interval. However, adverse events have indeed been reported after chronic dosing in patients.
About 2 decades ago, Walley et al 33 reported that a depressed 54-year-old man receiving metoprolol 100 mg/d for IHD developed fatigue and severe bradycardia within 2 days of starting treatment with fluoxetine: his heart rate dropped from 64 bpm to 36 bpm. His heart rate returned to normal 5 days after fluoxetine was withdrawn. Metoprolol was replaced by sotalol, and fluoxetine was reintroduced; there was no recurrence of bradycardia. Severe sinus bradycardia was also reported by McCollum et al 36 after bupropion was added to ongoing treatment with metoprolol.
Onalan et al 37 reported a 63-year-old woman who developed complete atrioventricular heart block 15 days after the addition of metoprolol (50 mg/d) to ongoing treatment with paroxetine (20 mg/d). Metoprolol was discontinued, and paroxetine treatment was also stopped several days later. After 5 further days, the heart block spontaneously resolved. No bradyarrhythmia was observed after challenge with similar doses of either metoprolol or paroxetine alone. The patient remained free of bradyarrhythmia at 2-and 3-year follow-up.
Goryachkina et al 9 studied 17 patients with acute myocardial infarction, all of whom were receiving metoprolol as a routine part of their therapy and paroxetine for depression. The authors found that paroxetine quadrupled the metoprolol AUC. In 2 (12%) of the patients, the dose of metoprolol had to be reduced because of excessive bradycardia and severe orthostatic hypotension. A quick reference to Tables 2 and 3 will explain why the interactions described in this and earlier sections occurred.
There is a theoretical risk that severe bradycardia and hypotension associated with raised levels of β-blockers may result in falls and fractures in the elderly. Although this does not appear to be a problem at the population level, 38, 39 risk in individual vulnerable patients cannot be ruled out.
Patients vulnerable to adverse effects associated with raised levels of β-blockers include the elderly, those with poor left ventricular systolic function, those with asthma or other bronchospastic disease, and those with unrecognized cardiac conduction problems. 7 
Action Points
Reference to Tables 2 and 3 can help clinicians anticipate potential pharmacokinetic drug interactions between antidepressant drugs and β-blockers. Clinicians may wish to avoid prescribing an antidepressant that risks an interaction, or, if they do prescribe such an antidepressant, they would need to down-titrate the dose of the β-blocker (that the patient is receiving) using the patient's heart rate and blood pressure as a guide.
Additional Notes
The effects of CYP2D6 inhibitors (Table 3) on the β-blockers that are metabolized by this enzyme (Table 2) are most apparent in persons who are CYP2D6 extensive metabolizers; that is, the majority of the population. This is because CYP2D6 poor metabolizers already have the equivalent of an inhibited form of the enzyme. CYP2D6 poor metabolizers comprise about 0%-14% of the population, depending on geographical origin. 11 Carvedilol and bisoprolol are P-glycoprotein substrates, 3, 40 and paroxetine and sertraline both inhibit P-glycoprotein. 41 However, the impact of paroxetine or sertraline use on the transport of carvedilol and bisoprolol is presently unclear.
Interactions With Fruit Juice
Clinicians who have read up to this point may also be interested to learn that fruit juice can reduce the absorption of some β-blockers. For example, orange juice 42, 43 and apple juice 44 have both been reported to reduce the oral bioavailability of atenolol. 
